Thymidylate synthase–dihydrofolate reductase–folylpolyglutamate synthetase complex

The so-called "thymidylate synthase–dihydrofolate reductase–folylpolyglutamate synthetase complex" refers collectively to three key enzymes involved in folic acid-dependent one-carbon metabolism essential for DNA synthesis. Thymidylate synthase catalyzes the methylation of deoxyuridine monophosphate into deoxythymidine monophosphate using methylenetetrahydrofolic acid as a cofactor; this reaction produces dihydrofolic acid as a byproduct that must be reduced back into tetrahydrofilc acid by dihydrofilc reductaseto sustain further cycles. Folypoly-glu-tama-te syn-the-tas-e adds glutamic acids onto folates/antifolates inside cells—a modification required both for retention within cells and optimal interaction with metabolic enzymes including those above. These pathways are tightly coupled functionally but do not form a single stable trimeric protein complex in humans; however, substrate channeling between thymidilate syn-tha-seand di-hyd-ro-folate re-du-c-ta-se has been demonstrated both experimentallyand computationally,[6] while bifunctional fusion proteins exist naturally only among certain lower eukaryotes such as protozoa.[8] All three are validated therapeutic targets—especially in oncology—for antifolate chemotherapies that disrupt nucleotide biosynthesis required by proliferating cancer cells.[3][6][7]

Other names

Thymidylate synthase (TS)Dihydrofolate reductase (DHFR)Folylpolyglutamate synthetase (FPGS)TS-DHFR bifunctional enzyme (in protozoa)Folypoly-gamma-glutamate synthetase

Thymidylate synthase inhibitors block dTMP synthesis from dUMP, leading to DNA damage and cell death due to thymineless death. Dihydrofolate reductase inhibitors prevent regeneration of tetrahydrofolic acid from dihydrofolic acid, depleting reduced folates needed for nucleotide biosynthesis. Antifolate drugs require polyglutamylation by FPGS for cellular retention and increased binding affinity to their targets.